УПРАВЛЕНИЕ НЕЖЕЛАТЕЛЬНЫМИ ЯВЛЕНИЯМИ, ВОЗНИКАЮЩИМИ НА ФОНЕ ПРИЕМА ПЕРАМПАНЕЛА
Abstract
.
About the Author
И. Жидкова
Московский государственный медико-стоматологический университет имени А. И. Евдокимова, Москва; Невромед-клиника, Москва
Russian Federation
Russian Federation
References
1. French J.A. et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012; 79: 589-96.
2. French J.A. et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305. Epilepsia. 2013; 54: 117-25.
3. Krauss G.L. et al. Randomized phase III study 306: adjunctive perampanel for partial onset seizures. Neurology. 2012; 78: 1408-15.
4. Krauss G.L. et al. Perampanel, a selective, noncompetitive a-amino-3- hydroxy-5-methyl-4-isooxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onsetseizures: Interim results from phase III, extension study 307. Epilepsia. 2013; 54: 126-34.
5. Rektor I. et al. Perampanel Study 207: long term open label evaluation in patients with epilepsy. Acta Neurol Scand 2012; 126: 263-9.
6. Steinhoff B.J. et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013; 54 (8): 1481-9.
7. Franco V. et al. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res. 2013; 70: 35-40.
8. Davies S., Heyman I., Goodman R. A population survey of mental health problems in children with epilepsy. Dev Med Child Neurol. 2003; 45: 292-5.
9. Инструкция по медицинскому применению прапарата Файкомпа РУ ЛП 002200 от 23.08.2013.
For citation:
. . Epilepsy and paroxysmal conditions. 2014;6(5):13-15. (In Russ.)
Views: 87
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
